GlobeNewswire Inc.··Bridgebio Pharma, Inc.BridgeBio's Acoramidis Cuts Mortality Risk in Half for Rare Heart Disease
BridgeBio reports acoramidis cuts all-cause mortality 44.7% and cardiovascular mortality 49.3% in ATTR-CM patients at Month 54 versus placebo.
BBIOFDA approvalclinical trial